• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter

    Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year

    Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year

    Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time

    TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025.

    Financial Highlights for the Quarter Ended September 30, 2025

    • Total revenue for the quarter was $9.2 million, compared to $4.4 million for the quarter ended September 30, 2024.
      • Revenue from operations from the consumer brands business totaled $3.2 million.
      • Digital Asset Revenue, which primarily consists of staking income, totaled $6.1 million.
    • Gross profit totaled $8.3 million, up 183% year-over-year due mainly to the addition of Digital Asset Revenue.
    • Net Income totaled $66.7 million, or $1.21 per share, compared to a net loss of $1.6 million, or ($1.55) per share, for the quarter ended September 30, 2024. This increase was largely the result of approximately $78.00 million in unrealized gain on our Solana treasury.
    • Cash and Cash Equivalents were $2.2 million as of September 30, 2025.
    • As of November 12, 2025 the Company had 59,918,609 shares of common stock outstanding.

    "Early in 2025, we enhanced our cash management and treasury strategy to include holding the cryptocurrency Solana directly on our balance sheet. Today, substantially all our Solana is generating a meaningful yield, effectively turning our treasury into a productive, revenue-generating asset," said Allan Marshall, Chief Executive Officer of Upexi. "We are pleased to report that this strategy delivered first quarter 2026 Digital Asset Revenue of $6.1 million and drove gross profit to $8.3 million, up 183% versus the year-ago quarter and a strong validation of our model. We are extremely proud of our progress as we continue to build the leading Solana treasury company, and we remain laser-focused on creating value for shareholders."

    Operational and Other Highlights During and Subsequent to the Quarter

    • Closed a $200 million concurrent private placement of common stock and convertible notes.
    • Announced a $500 million equity line agreement with A.G.P. to accelerate the growth of the Solana treasury strategy.
    • Held a Special Meeting of Stockholders where stockholders approved increasing the number of shares the Company may issue, at its sole discretion, under its equity line.
    • Established the Upexi Advisory Committee and added Arthur Hayes, S◎L Big Brain, and Jon Najarian as members.
    • Attended investor conferences, including: Canaccord Genuity 45th Annual Growth Conference, 5th Annual Needham Virtual Crypto Conference, H.C. Wainwright 27th Annual Global Investment Conference, FT Partners FinTech Conference 2025, A.G.P.'s Digital Asset Treasury Showcase, Maxim Growth Summit, New Orleans Investment Conference, Uncorrelated Cayman 2025, and Cantor Crypto & AI/Energy Infrastructure Conference.

    The Company's Quarterly Report on Form 10-Q for this period is available on the SEC's website and on Upexi's IR website.

    Conference Call Information

    Event:First Quarter 2026 Earnings Call
    Date:Tuesday, November 11, 2025
    Time:5:30 p.m. ET
    Live Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)
    Webcasthttps://ir.upexi.com/news-events/ir-calendar



    For interested individuals unable to join the conference call, a dial-in replay of the call will be available until November 25, 2025, and can be accessed by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International) and entering replay pin number: 13757131.

    About Upexi, Inc.

    Upexi, Inc. (NASDAQ:UPXI) is a leading digital asset treasury company, where it aims to acquire and hold as much Solana (SOL) as possible in a disciplined and accretive fashion. In addition to benefiting from the potential price appreciation of Solana - the cryptocurrency of the leading high-performance blockchain - Upexi utilizes three key value accrual mechanisms in intelligent capital issuance, staking, and discounted locked token purchases. The Company operates in a risk-prudent fashion to position itself for any market environment and to appeal to investors of all kinds, and it currently holds over two million SOL. Upexi also continues to be a brand owner specializing in the development, manufacturing, and distribution of consumer products. Please see www.upexi.com for more information.

    Follow Upexi on X - https://x.com/upexitreasury

    Follow CEO, Allan Marshall, on X - https://x.com/upexiallan

    Follow CSO, Brian Rudick, on X - https://x.com/thetinyant

    Forward-Looking Statements

    This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. For example, the Company is using forward looking statements when it discusses the anticipated use of proceeds. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration, and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward- looking statements. Although we believe that the beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

    Company Contact

    Brian Rudick, Chief Strategy Officer

    Email: [email protected]

    Phone: (203) 442-5391

    Investor Relations Contact

    KCSA Strategic Communications

    Valter Pinto or Jack Perkins

    [email protected]

    Media Relations Inquiries

    Greg or Katie @STiR-communications.com

    STiR-communications.com

    UPEXI, INC.     
    CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)    
          
     September 30,  June 30, 
     2025  2025 
     (Unaudited)    
    ASSETS     
    Current assets     
    Cash$2,237,223  $2,975,150 
    Accounts receivable, net 284,261   157,515 
    Inventory, net 1,035,680   1,152,870 
    Due from VitaMedica transition 471,380   228,017 
    Prepaid expenses and other receivables 1,480,227   350,836 
    Current digital assets at fair value 212,832,396   49,913,655 
    Purchase price receivable - VitaMedica 2,000,000   2,000,000 
    Total current assets 220,341,167   56,778,043 
            
    Property and equipment, net 1,931,498   2,052,573 
    Intangible assets, net 143,923   163,113 
    Goodwill 848,854   848,854 
    Deferred tax asset 5,948,858   5,948,858 
    Investment in digital company 750,000   - 
    Digital assets at fair value, net of current 187,993,435   56,083,525 
    Other assets 200,690   192,123 
    Right-of-use asset, net 1,569,742   1,739,755 
    Total other assets 199,387,000   67,028,801 
            
    Total assets$419,728,167  $123,806,844 
            
    LIABILITIES AND STOCKHOLDERS' EQUITY       
    Current liabilities       
    Accounts payable$2,184,897  $1,039,370 
    Accrued compensation 3,176,969   3,470,296 
    Deferred revenue 51,347   13,155 
    Accrued liabilities 947,076   356,064 
    Accrued interest 1,545,481   792,449 
    Acquisition payable 260,652   260,652 
    Current portion of promissory notes 560,000   560,000 
    Short-term treasury debt 50,000,000   20,000,000 
    Current portion of Cygnet subsidiary notes payable 5,380,910   5,380,910 
    Current portion of operating lease payable 521,702   691,010 
    Total current liabilities 64,629,034   32,563,906 
            
    Operating lease payable, net of current portion 1,145,439   1,145,440 
    Convertible notes payable 143,161,862   - 
            
    Total long-term liabilities 144,307,301   1,145,440 
            



    Stockholders' equity     
    Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 and 150,000 shares issued and outstanding, respectively 2   2 
    Common stock, $0.00001 par value, 300,000,000 shares authorized, and 58,893,261 and 38,270,571 shares issued and outstanding, respectively 589   383 
    Additional paid in capital 204,586,941   150,640,935 
    Retain earnings (accumulated deficit) 6,204,300   (60,543,822)
    Total stockholders' equity 210,791,832   90,097,498 
            
    Total liabilities and stockholders' equity$419,728,167  $123,806,844 

      

    UPEXI, INC.  
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)  
       
     Three Months Ended September 30, 
     2025  2024 
          
    Revenue     
    Revenue$3,156,128  $4,356,515 
    Digital asset revenue 6,083,617   - 
    Total revenue 9,239,745   4,356,515 
            
    Cost of revenue 956,745   1,426,447 
            
    Gross profit 8,283,000   2,930,068 
            
    Operating expenses       
    Sales and marketing 1,067,555   1,041,425 
    Distribution costs 887,596   1,455,725 
    General and administrative 9,257,208   1,367,690 
    Unrealized (gain) on digital assets (77,996,124)  - 
    Share-based compensation 5,756,398   141,298 
    Amortization of acquired intangible assets 19,190   19,190 
    Depreciation 135,902   239,905 
      (60,872,275)  4,265,233 
            
    Income (loss) from operations 69,155,275   (1,335,165)
            
    Other income (expense), net       
    Interest expense, net (2,699,383)  (290,412)
    Other income, net 292,230   - 
    Other expense, net (2,407,153)  (290,412)
            
    Income (loss) on operations before income tax 66,748,122   (1,625,577)
            
            
    Income tax benefit (expense) -   - 
            
    Net income (loss) from continuing operations$66,748,122  $(1,625,577)
            
    Basic income (loss) per share:       
    Income (loss) per share$1.21  $(1.55)
            
    Diluted income (loss) per share:       
    Income (loss) per share$0.76  $(1.55)
            
    Basic weighted average shares outstanding 55,340,634   1,045,429 
    Fully diluted weighted average shares outstanding 88,479,950   1,045,429 


    Primary Logo

    Get the next $UPXI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    11/12/25 4:06:12 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Upexi Inc.

    10-Q - UPEXI, INC. (0001775194) (Filer)

    11/12/25 6:10:19 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B3 filed by Upexi Inc.

    424B3 - UPEXI, INC. (0001775194) (Filer)

    11/10/25 6:14:21 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $799,998 worth of shares (161,943 units at $4.94) and was granted 1,200,000 shares, increasing direct ownership by 154% to 2,246,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:08 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025 Total revenue for the quarter was $9.2 mill

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Clear Street's Disruptive Technology Conference Convenes this Month in Palm Beach

    Invitation-only event features CEOs, investors and innovators across AI, Digital Assets, Fintech and beyond Keynote speakers Michael Saylor and Eric Trump highlight lineup of thought leaders NEW YORK and PALM BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Clear Street, ("Clear Street", "the Company") a cloud-native financial infrastructure technology firm on a mission to give sophisticated investors access to every asset in every market, will host its Disruptive Technology Conference on November 19–20, 2025, at the Four Seasons Resort Palm Beach, Florida. The two-day, invitation-only event brings together a select group of CEOs, institutional investors and pioneering industry leaders fo

    11/7/25 2:30:00 PM ET
    $ABTC
    $BKKT
    $CLSK
    EDP Services
    Technology
    Finance: Consumer Services
    Finance

    Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

    TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November 11, 2025. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi First Quarter 2026 Earnings CallDate:Tuesday, November 11, 2025Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar Fo

    11/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    CSO Rudick Brian Benjamin was granted 400,000 shares, increasing direct ownership by 91% to 838,597 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:09:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Financials

    Live finance-specific insights

    View All

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025 Total revenue for the quarter was $9.2 mill

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

    TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November 11, 2025. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi First Quarter 2026 Earnings CallDate:Tuesday, November 11, 2025Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar Fo

    11/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025

    TAMPA, Fla., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its financial results for the fiscal year ended June 30, 2025. The annual report is available on either the SEC's website or on Upexi's IR website. Financial Highlights for the Fiscal Year ended June 30, 2025: Revenue totaled $15.8 million.Gross profit totaled approximately $10.7 million, representing a gross margin of 67%.Net loss totaled approximately $13.7 million.As of September 10, 2025, there are 58,893,261 shares of

    9/24/25 5:55:38 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Leadership Updates

    Live Leadership Updates

    View All

    Upexi Welcomes Jon Najarian to the Upexi Advisory Committee

    TAMPA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced the addition of Jon Najarian (Twitter: @jonnajarian) to the Upexi Advisory Committee, joining Arthur Hayes and S◎L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Marke

    10/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care